Xalatan is an eye drop used to reduce elevated intraocular pressure (IOP) in adults with primary open‑angle glaucoma and ocular hypertension. Lowering IOP helps protect the optic nerve, slowing the progression of glaucoma and preserving vision. Xalatan contains latanoprost, a prostaglandin analog that enhances the outflow of aqueous humor (the fluid inside your eye) through the uveoscleral pathway. By improving fluid drainage rather than reducing fluid production, it offers sustained around‑the‑clock pressure control with once‑daily dosing.
Many clinicians choose Xalatan as a first‑line therapy because it is effective, convenient, and generally well tolerated. It can be used alone (monotherapy) or alongside other glaucoma medications, such as topical beta blockers, carbonic anhydrase inhibitors, or alpha agonists, when additional IOP lowering is needed. Patients commonly start to see pressure reductions within 3–4 hours of the first dose, with the maximum effect typically observed after about 8–12 hours. With continued, consistent use, the IOP‑lowering benefit is maintained over the long term.
Beyond glaucoma, Xalatan may be considered in ocular hypertension when sustained elevated pressure puts the eye at risk, even without definitive signs of optic nerve damage. Your eye care professional will tailor therapy based on your baseline pressure, target IOP, optic nerve status, and tolerance of the drop.
The usual adult dose of Xalatan is one drop in the affected eye(s) once daily in the evening. Do not exceed once‑daily use. More frequent dosing can reduce effectiveness and may increase the risk of side effects. Always follow your prescriber’s instructions for your specific condition.
How to apply: 1) Wash your hands. 2) If you wear soft contact lenses, remove them before instillation because the preservative (often benzalkonium chloride) can be absorbed by lenses; wait at least 15 minutes before reinserting. 3) Tilt your head back, gently pull down the lower eyelid to create a small pocket, and instill one drop without touching the bottle tip to your eye or skin. 4) Close your eye and apply gentle pressure to the inner corner (nasolacrimal occlusion) for 1–2 minutes to limit systemic absorption and enhance local effect. 5) Blot excess fluid; avoid blinking vigorously.
If you use multiple ophthalmic products, separate each by at least 5 minutes to prevent washout. If switching from another glaucoma medicine, use as directed by your clinician; commonly, you complete one agent and start Xalatan the next day. Keep follow‑up appointments to assess IOP response and adjust therapy as needed.
Xalatan can gradually change the color of the iris by increasing brown pigment, especially in eyes with mixed colors (e.g., green‑brown, hazel). This change is typically permanent and more noticeable when only one eye is treated. Eyelid skin may darken, and eyelashes can grow longer, thicker, and darker; lash changes often reverse after stopping, but pigment changes may not.
Use caution if you have a history of ocular inflammation (iritis/uveitis), macular edema (including cystoid macular edema), or risk factors such as aphakia or pseudophakia with a torn posterior lens capsule. Prostaglandin analogs can exacerbate inflammation or precipitate edema in susceptible patients. People with a history of herpetic keratitis should be monitored carefully, as recurrences have been reported with prostaglandin therapy.
Temporary blurred vision or mild stinging can occur after instillation. Avoid driving or operating machinery until vision clears. If you have severe dry eye, ocular surface disease, or sensitivity to preservatives, discuss preservative‑free or alternative formulations with your eye care professional. Tell your clinician about all eye conditions, systemic diseases (including asthma), and all medicines or supplements you use.
Pregnancy and lactation: Human data are limited. Use only if the potential benefit justifies potential risk. If you are pregnant, planning pregnancy, or breastfeeding, consult your healthcare provider. Pediatric and geriatric use should be individualized with careful monitoring.
Do not use Xalatan if you are hypersensitive to latanoprost or any component of the formulation. Active ocular infections or significant intraocular inflammation warrant careful evaluation before starting therapy; while not absolute contraindications, they may require alternative approaches or close monitoring. Always inform your clinician about prior herpetic eye disease, recent eye surgery, or any new eye symptoms before initiating or continuing treatment.
Common side effects include mild to moderate conjunctival hyperemia (eye redness), transient stinging or burning on instillation, itching, foreign‑body sensation, dry eye, and blurred vision. Many of these effects lessen as your eyes adapt. Eyelash growth and eyelid skin darkening are frequent with chronic use. Iris pigmentation changes can occur gradually over months; these are more likely in eyes with mixed colors and are usually permanent.
Less common side effects include eye pain, photophobia (light sensitivity), punctate keratitis, and periorbital fat atrophy (leading to a deeper upper lid sulcus). Rare but important events include uveitis, keratitis, cystoid macular edema, or reactivation of herpetic keratitis in predisposed individuals. Discontinue and seek prompt evaluation if you notice severe eye pain, marked vision changes, persistent light sensitivity, halos, or a sudden increase in floaters.
Systemic effects are uncommon because systemic absorption is minimal, especially when you perform nasolacrimal occlusion. Rarely, headache, dizziness, or exacerbation of asthma has been reported. If you suspect an allergic reaction (e.g., swelling, rash, breathing difficulty), stop using the drop and seek medical care immediately.
Report ongoing irritation, progressive redness, or any new symptom to your eye care professional. Never stop glaucoma therapy without medical guidance, as stopping abruptly can allow IOP to rise and may risk optic nerve damage.
Avoid using two prostaglandin analogs simultaneously (for example, latanoprost with bimatoprost or travoprost) unless specifically directed by an eye specialist. Concurrent prostaglandin therapy can paradoxically increase IOP or diminish efficacy. If your regimen requires multiple agents, your clinician will choose complementary classes such as beta blockers, alpha agonists, or carbonic anhydrase inhibitors.
When using multiple ophthalmic products, separate instillations by at least 5 minutes to reduce washout and potential compatibility issues, and apply gels/ointments last. Inform your provider about all eye drops, over‑the‑counter lubricants, allergy drops, and any systemic medications you take. While significant systemic drug interactions are uncommon with topical latanoprost, your full medication list helps your clinician optimize safety and effectiveness.
If you miss a dose, apply one drop as soon as you remember unless it is close to the time of your next scheduled dose. If it is near the next dose, skip the missed dose and resume your regular once‑daily evening schedule. Do not use extra drops to make up for a missed dose, as more frequent dosing can reduce effectiveness.
Accidental ocular overdose may cause increased irritation, redness, or tearing. Rinse the eye with sterile saline or clean water if excessive drops are instilled. Serious systemic toxicity is unlikely from topical use. If someone swallows Xalatan or experiences severe or persistent symptoms after overdose, contact Poison Control (1‑800‑222‑1222 in the U.S.) or seek urgent medical care for guidance.
Follow your product’s label for storage instructions, as they may vary by brand or generic. Unopened Xalatan is commonly stored refrigerated (36°F–46°F / 2°C–8°C). After opening, many formulations can be kept at room temperature for a limited time (often up to 6 weeks); keep the cap tightly closed, protect from light, and do not freeze. Always check the specific expiration period after opening printed on your carton or bottle, and discard any remaining solution after that window or by the labeled expiration date, whichever comes first.
Keep out of reach of children and pets. Do not use if the solution changes color, becomes cloudy, or if the tamper‑evident seal is broken before first use. Store the bottle upright when possible to help maintain dropper integrity and dosing accuracy.
In the United States, Xalatan is a prescription medication. However, Culpeper Regional Health System offers a legal and structured solution that enables eligible adults to buy Xalatan without prescription in the traditional sense of an in‑person office visit. Through a compliant telehealth intake, your information is reviewed by a licensed clinician or pharmacist operating under state‑approved protocols. When appropriate, an electronic order is issued and dispensed from a U.S.‑licensed pharmacy, complete with counseling and follow‑up.
This pathway is designed to meet federal and state requirements while improving access for stable patients who need timely refills or convenient starts. Safeguards include identity and age verification, clinical screening for red flags, dose checks, drug‑interaction review, required patient education, and clear guidance on when to seek in‑person eye care. Supply is typically limited to safe dispensing quantities, and ongoing use may require periodic telehealth reassessment or documentation of recent eye exams.
Why choose this option? It provides a secure alternative to risky overseas pharmacies, helps prevent counterfeit products, and keeps your care within a U.S. regulatory framework. To begin, visit Culpeper Regional Health’s program page, complete the short questionnaire, and be ready to share your medication history and eye doctor’s information if available. If the clinician determines Xalatan is not suitable, you will be directed to appropriate care. If approved, orders are processed quickly with transparent pricing and discreet shipping.
Important: Telehealth access is not a substitute for comprehensive eye examinations. Glaucoma requires periodic IOP checks and optic nerve assessment. Use this service to streamline access, but continue regular follow‑ups with your eye care professional to protect your vision.
Xalatan is latanoprost 0.005% eye drops, a prostaglandin analog used once daily to lower intraocular pressure in open-angle glaucoma or ocular hypertension by increasing uveoscleral outflow.
Pressure lowering usually begins in 3–4 hours, peaks around 8–12 hours, lasts about 24 hours with nightly dosing, and reaches full steady benefit after 3–4 weeks.
Instill one drop in the affected eye(s) once nightly; wash hands, avoid touching the dropper tip, close eyes gently and press the inner corner for 1–2 minutes, and do not use it more than once daily.
If you forget a dose, use it when you remember unless it is close to the next dose; skip the missed one and do not double up.
Yes, it is often combined with other classes (beta-blockers, carbonic anhydrase inhibitors, alpha agonists); separate different drops by at least 5–10 minutes and avoid using two prostaglandin analogs together.
Mild eye redness, irritation or stinging on instillation, dry eye symptoms, and gradual eyelash growth or eyelid skin darkening are common.
Possible permanent iris darkening (especially in mixed-color irides), prostaglandin-associated periorbitopathy (eyelid/under-eye hollowing), rare macular edema or flare of uveitis/herpetic keratitis; seek care for severe pain, sudden vision changes, or marked inflammation.
It can darken the iris over months (more likely in hazel/green-brown eyes) and increase lash length, thickness, and number; iris color change may be permanent, while lash and skin changes usually reverse after stopping.
Remove soft lenses before instillation because the preservative benzalkonium chloride can be absorbed; wait at least 15 minutes before reinserting lenses.
Keep unopened bottles refrigerated (2–8°C); after opening, most labels allow room temperature storage for up to 6 weeks and protection from light—follow the instructions for your specific product.
Human data are limited; use only if the expected benefit outweighs potential risks as determined with your ophthalmologist, and use caution while breastfeeding due to uncertain excretion.
Latanoprost has established safety and effectiveness in pediatric patients and is used for pediatric glaucoma under specialist supervision, typically once nightly.
Avoid if you are allergic to latanoprost or any ingredient; use caution if you have active ocular inflammation, a history of herpetic keratitis, are aphakic/pseudophakic with a torn posterior capsule, or are at risk for macular edema.
Using it more often can reduce its pressure-lowering effect and increase side effects; return to once-nightly dosing and contact your clinician if significant irritation occurs.
On average, intraocular pressure decreases by about 25–35% from baseline, though individual responses vary; your eye doctor will monitor and adjust your regimen as needed.
Your surgeon may adjust or temporarily pause prostaglandin analogs around surgery in patients at risk for macular edema; follow individualized perioperative instructions.
Clinically significant systemic interactions are uncommon; do not use multiple prostaglandin analogs concurrently, and space other topical medications by several minutes to prevent washout.
Bedtime dosing is preferred and provides consistent 24-hour control; avoid morning or twice-daily use unless directed otherwise.
Use punctal occlusion (press the inner corner of the eye for 1–2 minutes) and keep the eye gently closed after instillation; allow other drops or contact lenses to be separated by time.
Xalatan contains benzalkonium chloride (BAK), which can aggravate dry eye or irritate frequent contact lens wearers; preservative-free latanoprost options exist if sensitivity occurs.
They share the same active ingredient and comparable efficacy; generics are typically less expensive, though inactive ingredients and bottle designs may differ and affect comfort or shelf life.
Both are effective once-daily prostaglandin analogs with similar pressure reduction; travoprost may cause more redness in some patients, and Travatan Z uses the SofZia preservative instead of BAK.
Bimatoprost can yield slightly greater average intraocular pressure reduction but often with higher rates of conjunctival hyperemia and periocular changes; choice depends on efficacy needs and tolerability.
Efficacy is comparable; Zioptan’s single-use, preservative-free vials suit patients with dry eye or preservative sensitivity, though cost and refrigerated storage before use may be considerations.
Vyzulta donates nitric oxide to also enhance trabecular outflow and may lower pressure slightly more on average; it usually costs more and, like Xalatan, contains BAK and often requires refrigeration before opening.
Rocklatan combines latanoprost with netarsudil and generally provides greater pressure reduction than either agent alone but with more redness; it’s considered when monotherapy is insufficient.
Both are latanoprost 0.005% with similar efficacy; Iyuzeh is preservative-free in a multidose bottle, which can improve comfort for patients sensitive to BAK.
All standard prostaglandin analogs are dosed once nightly; more frequent use can paradoxically reduce efficacy and increase side effects.
All can cause redness, lash growth, and iris darkening; hyperemia tends to be more frequent with bimatoprost and travoprost than with latanoprost, and preservative-free options may sting less.
Preservative-free options such as Zioptan or Iyuzeh may be more comfortable; Travatan Z uses an alternative preservative; with Xalatan’s BAK, remove lenses and wait 15 minutes before reinserting.
Xalatan, Vyzulta, and Rocklatan are commonly refrigerated before opening, with limited room-temperature time after opening; Lumigan and Travatan Z are typically stored at room temperature; always follow the product label.
Generic latanoprost is usually the least expensive; brand-name prostaglandin analogs (Xalatan, Vyzulta, Rocklatan, Zioptan) often cost more, though insurance coverage and regional pricing vary.
All agents in this class, including latanoprost, are effective in normal-tension glaucoma; the “best” choice depends on target pressure, nocturnal IOP profile, side effects, and individual response.
Yes, some patients respond better or tolerate side effects differently when switching within the class, though many clinicians add a second class if target IOP is not met.
Lets get in touch if you have any questions.